Midcap

Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Tuesday, October 19, 2021 - 9:05pm

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Bird Announces Upsizing of Vehicle Financing Credit Facility with Apollo to $150 Million

Thursday, October 14, 2021 - 2:00pm

Yibo Ling, Chief Financial Officer at Bird, commented, "We are pleased to have delivered against our stated objective to expand our vehicle financing capabilities through the upsizing of our credit facility.

Key Points: 
  • Yibo Ling, Chief Financial Officer at Bird, commented, "We are pleased to have delivered against our stated objective to expand our vehicle financing capabilities through the upsizing of our credit facility.
  • This commitment from Apollo reflects further confidence in the strong cash generating capabilities of our electric vehicle fleet enabled by our multi-year track record of over 100 million rides.
  • With the increased liquidity provided by the upsized facility, we believe we are well positioned to support our expansion plans."
  • Apollo Managing Director, Aaron Kless said, "We are pleased to support Bird through the upsizing of the credit facility, helping the Company to enhance its vehicle financing capabilities and execute on its strategy.

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Thursday, October 14, 2021 - 1:00pm

Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.

Key Points: 
  • Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.
  • Following the U.S. Food and Drug Administrations (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkins lymphoma (NHL).
  • View the full release here: https://www.businesswire.com/news/home/20211014005549/en/
    XL114 is the second molecule that Exelixis in-licensed from Aurigene under the companies July 2019 collaboration, option and license agreement.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

F.N.B. Corporation Schedules Third Quarter 2021 Earnings Report and Conference Call

Wednesday, October 6, 2021 - 9:30pm

Corporation (NYSE: FNB) announced today that it plans to issue financial results for the third quarter of 2021 after the market close on Monday, October 18, 2021.

Key Points: 
  • Corporation (NYSE: FNB) announced today that it plans to issue financial results for the third quarter of 2021 after the market close on Monday, October 18, 2021.
  • Participants are encouraged to pre-register for the conference call at: https://dpregister.com/10160901 .
  • Callers who pre-register will be provided a conference passcode and unique PIN to bypass the live operator and gain immediate access to the call.
  • Dial-in Access: The conference call may be accessed by dialing 844-802-2440 (for domestic callers) or 412-317-5133 (for international callers).

STRATA Skin Sciences Announces CFO Transition

Monday, October 4, 2021 - 9:05pm

Having previously worked with Chris at Encore Dermatology, where he successfully led the financial organization, we were delighted to add him to the STRATA team.

Key Points: 
  • Having previously worked with Chris at Encore Dermatology, where he successfully led the financial organization, we were delighted to add him to the STRATA team.
  • In an 8-K filed today, STRATA announced that it has completed an $8 million financing with MidCap Financial Trust (MidCap).
  • STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
  • Its products include the XTRAC and now Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

FNB Wins Bank Customer Experience Award

Wednesday, September 29, 2021 - 3:00pm

Corporation (NYSE: FNB) announced that its largest subsidiary, First National Bank, was named the winner in the best mobile experience category as part of the Bank Customer Experience (BCX) Awards.

Key Points: 
  • Corporation (NYSE: FNB) announced that its largest subsidiary, First National Bank, was named the winner in the best mobile experience category as part of the Bank Customer Experience (BCX) Awards.
  • One of only four 2021 winners, FNB joins some of the largest and most renowned financial institutions, globally and in the U.S., in being recognized for its innovative customer experience.
  • FNB received the award for its multi-channel Clicks-to-Bricks strategy, which includes a fully digital bank to integrate the in-branch, online and mobile banking experiences.
  • "Receiving this latest recognition for our world-class mobile platform affirms that our significant investments in technology have resulted in a customer experience that sets FNB apart," said Samuel D. Kirsch, Chief Digital Officer of First National Bank.

FNB Delivers More Than $7 Million for Hill District in Pittsburgh

Wednesday, September 22, 2021 - 5:30pm

Corporation (NYSE: FNB) announced it has delivered an initial payment of nearly $7.2 million to the Greater Hill District Reinvestment Fund to support community investment and development.

Key Points: 
  • Corporation (NYSE: FNB) announced it has delivered an initial payment of nearly $7.2 million to the Greater Hill District Reinvestment Fund to support community investment and development.
  • With a long history of service to the community, FNB's total investment in the Hill District is in excess of $200 million in loans, investments and grants.
  • The Company will continue to deepen its support in the Hill District and Pittsburgh region overall as the FNB Financial Center development progresses, with completion anticipated in 2023.
  • Corporation (NYSE: FNB), headquartered in Pittsburgh, Pennsylvania, is a diversified financial services company operating in seven states and the District of Columbia.